Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3991213 | 0.89 | TRAP1 (0.34) | MAOBPTGER4P2RX7FSCN1PIK3CA | |
| SCHEMBL3991527 | 0.89 | P2RX7 (0.36) | MAOBP2RX7 | |
| SCHEMBL3987232 | 0.88 | PTGER4 (0.35) | MAOBPTGER4P2RX7FSCN1PIK3CA | |
| SCHEMBL3991571 | 0.88 | AVPR1B (0.36) | MAOBPTGER4P2RX7FSCN1 | |
| SCHEMBL3988126 | 0.87 | PTGER4 (0.34) | MAOBPTGER4P2RX7FSCN1PIK3CA | |
| SCHEMBL3990945 | 0.87 | P2RX7 (0.36) | PTGER4P2RX7FSCN1 | |
| SCHEMBL3983915 | 0.87 | P2RX7 (0.37) | MAOBPTGER4P2RX7FSCN1PIK3CA | |
| SCHEMBL3986668 | 0.86 | PTGDR2 (0.40) | PTGER4PIK3CA | |
| SCHEMBL3985744 | 0.86 | P2RX7 (0.35) | PTGER4P2RX7FSCN1SOS1 | |
| SCHEMBL3985871 | 0.86 | P2RX7 (0.36) | PTGER4P2RX7FSCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | claimed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | MAOB 2049/4885HDAC1 568/4885HDAC7 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.